5852-78-8
5852-78-8 结构式
基本信息
8-羟基喹啉-5-羧酸
CS-1524
IOX-1
IOX 1
IOX 1, >=98%
5-Carboxy-8-hydroxyquinoline
JMJD2 Inhibitor, 5-carboxy-8HQ
8-hydroxy-5-Quinolinecarboxylic acid
8-Hydroxyquinoline-5-carboxylic Acid
5-Quinolinecarboxylic acid, 8-hydroxy-
5-Carboxy-8-hydroxyquinoline USP/EP/BP
物理化学性质
常见问题列表
IOX1 (0-200 µM; 2 hours) inhibits the proliferation and migration of vascular smooth muscle cells (VSMCs) stimulated with angiotensin II (Ang II) in a concentration-dependent manner. IOX1 (200 µM; 24 hours) blocks the cell cycle progression of angiotensin II (Ang II)-VSMCs by increasing the percentage of cells in the G0/G1 phase. IOX1 (50-200 µM; 2 hours) attenuates cyclin D1 and upregulates p21 mRNA levels in a concentration-dependent. IOX1 (50-200 µM; 2 hours) mediates cyclin D1 and p21 expression by regaining H3K9me3.
Cell Proliferation Assay
| Cell Line: | Vascular smooth muscle cells (VSMCs) |
| Concentration: | 50 μM, 100 μM, 200 μM |
| Incubation Time: | Pretreated 2 hours |
| Result: | Exhibited a decrease in proliferation and migration. |
Cell Cycle Analysis
| Cell Line: | Vascular smooth muscle cells (VSMCs) |
| Concentration: | 200 μM |
| Incubation Time: | 24 hours |
| Result: | Slowed down the progression of the cell cycle from the G0/G1 to the S phase. |
RT-PCR
| Cell Line: | Vascular smooth muscle cells (VSMCs) |
| Concentration: | 50 μM, 100 μM, 200 μM |
| Incubation Time: | 2 hours |
| Result: | Decreased cyclin D1 mRNA expression and increased p21 mRNA expression. |
RT-PCR
| Cell Line: | Vascular smooth muscle cells (VSMCs) |
| Concentration: | 50 μM, 100 μM, 200 μM |
| Incubation Time: | 2 hours |
| Result: | Enhanced the total protein levels of H3K9me3. |
IOX1 (5-c-8HQ) (oral gavage; 10-20 mg/kg; 12 days) inhibits tumor growth and attenuates the self-renewal of liver cancer stem-like cells (LCSCs) in vivo.
| Animal Model: | Six-week-old male BALB/c nude mice |
| Dosage: | 10 mg/kg, 20 mg/kg |
| Administration: | 12 days |
| Result: | Did not result in obvious adverse effects on mice as demonstrated by no body weight reduction and no toxicity to the major organs after treatment.Inhibited LCSC orthotopic graft tumor growth.Significantly reduced the protein levels of EpCAM and Sox9 in LCSC orthotopic graft tumors nhibited LCSC orthotopic graft tumor growth.Decreased Ki67-positive tumor cells and markedly reduced the tumorsphere formation abilities of LCSCs in a dose-dependent manner. |